OMERS ADMINISTRATION Corp Invests $1.36 Million in Alnylam Pharmaceuticals, Inc. $ALNY

OMERS ADMINISTRATION Corp bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,517 shares of the biopharmaceutical company’s stock, valued at approximately $1,360,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. MV Capital Management Inc. purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at about $25,000. HM Payson & Co. purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth about $27,000. Golden State Wealth Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $29,000. Finally, Manchester Capital Management LLC increased its position in Alnylam Pharmaceuticals by 600.0% during the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 72 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director directly owned 1,582 shares in the company, valued at approximately $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.4%

Shares of Alnylam Pharmaceuticals stock opened at $239.00 on Thursday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $197.81 and a 1-year high of $495.55. The company has a market capitalization of $31.98 billion, a PE ratio of 44.42 and a beta of 0.30. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The business has a 50-day moving average of $264.27 and a 200-day moving average of $294.77.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter in the prior year, the business posted ($0.51) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 66.9% on a year-over-year basis. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Royal Bank Of Canada cut their price target on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. HC Wainwright dropped their price objective on shares of Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $376.00 price target on shares of Alnylam Pharmaceuticals in a research report on Tuesday. Finally, Bank of America lowered their price target on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a report on Tuesday, July 14th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $386.14.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.